enfortumab vedotin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
Conditions
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
Trial Timeline
May 14, 2014 → Dec 7, 2022
NCT ID
NCT02091999About enfortumab vedotin
enfortumab vedotin is a phase 1 stage product being developed by Astellas Pharma for Metastatic Urothelial Cancer and Other Malignant Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02091999. Target conditions include Metastatic Urothelial Cancer and Other Malignant Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07139977 | Phase 2 | Recruiting |
| NCT07347314 | Phase 2 | Recruiting |
| NCT06862219 | Approved | Recruiting |
| NCT06891560 | Phase 2 | Recruiting |
| NCT06553885 | Phase 2 | Recruiting |
| NCT06394570 | Phase 1/2 | Recruiting |
| NCT06011954 | Pre-clinical | Recruiting |
| NCT05868265 | Phase 2 | Recruiting |
| NCT04754191 | Phase 2 | Active |
| NCT05014139 | Phase 1 | Terminated |
| NCT04995419 | Phase 2 | Completed |
| NCT03219333 | Phase 2 | Completed |
| NCT03070990 | Phase 1 | Completed |
| NCT02091999 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Urothelial Cancer and Other Malignant Solid Tumors